KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deffered Revenue: 2009-2022

Historic Non-Current Deffered Revenue for Halozyme Therapeutics (HALO) over the last 14 years, with Dec 2022 value amounting to $2.3 million.

  • Halozyme Therapeutics' Non-Current Deffered Revenue fell 20.47% to $2.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.3 million, marking a year-over-year decrease of 20.47%. This contributed to the annual value of $2.3 million for FY2022, which is 10.95% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $2.3 million for FY2022, which was down 10.95% from $2.5 million recorded in FY2021.
  • Halozyme Therapeutics' 5-year Non-Current Deffered Revenue high stood at $5.0 million for FY2018, and its period low was $1.2 million during FY2019.
  • In the last 3 years, Halozyme Therapeutics' Non-Current Deffered Revenue had a median value of $2.5 million in 2021 and averaged $2.9 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first tumbled by 90.78% in 2018, then surged by 222.85% in 2020.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Non-Current Deffered Revenue stood at $5.0 million in 2018, then slumped by 75.10% to $1.2 million in 2019, then soared by 222.85% to $4.0 million in 2020, then slumped by 37.16% to $2.5 million in 2021, then decreased by 10.95% to $2.3 million in 2022.